Upcoming Events
  1. Consumer training workshops

    July 17 @ 12:30 pm - 2:00 pm
  2. Conducting systematic reviews: A short course for thoracic oncology nurses

    August 5 @ 6:30 pm
  3. 6th ALTG Lung Cancer Preceptorship

    October 23 @ 10:00 am - October 24 @ 3:30 pm
  4. ALTG open MAC and SAC meetings

    November 20

Thoracic oncology highlights from ASCO2020 webinar- recording and evaluation survey

Please fill in the evaluation survey if you have not already done so by clicking on the survey icon at the base of your webinar console.

Please access the recording and evaluation survey here

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.

Lung Cancer PhD Scholarships – the Neville Bantoft Bequest

Through its National Lung Cancer Program Lung Foundation Australia (LFA) has facilitated a partnership between Australian universities and the Bantoft family to establish four co-funded lung cancer PhD scholarships supporting lung cancer researchers throughout the period 2013-2016.

The process began in 2011 when Mr John Bantoft contacted LFA to request a proposal for a bequest for his son, Neville, who was diagnosed and passed away from lung cancer aged 40. In discussions with the family it was identified that research into lung cancer, particularly non-smoking related lung cancer or lung cancer in the young, was their inspiration for the use of these funds.

LFA proposed to use the funds to encourage young researchers/clinicians to undertake lung cancer research via 3 year PhD Scholarships, to further understanding and potentially stimulate the next generation of doctors to become specialists or develop a special interest in lung cancer.

In 2013 expressions of interest from Universities around Australia were invited to partner, co-fund and administer the PhD scholarships for researchers commencing a higher degree. The University of Queensland, Edith Cowan University WA and University of Tasmania agreed to match or provide a greater contribution towards the scholarships in line with the NHMRC Standard or Clinical Stipend levels. A fourth scholarship was co-funded in 2014 by Federation University in Victoria.

  • The University of Queensland Thoracic Research Centre will address ways to translate molecular medicine for lung cancer patients. Diagnostic biopsies in lung cancer are usually small and a challenge for molecular testing. This PhD will examine ways of testing and finding actionable mutations and biomarkers that have clinical utility for improving outcomes for people with lung cancer through precision medicine.
  • University of Tasmania aims to assess the effectiveness of cell culture models of COPD with respect to epithelial to mesenchymal transition. Cell culture models will be used to further understanding of the molecular mechanism of COPD and its link to lung cancer and to test potential therapeutic agents.
  • Edith Cowan University is working to improve the lives of patients with lung cancer through the use of exercise as medicine. They are collaborating with Professor Gary Lee at Sir Charles Gairdner Hospital to study the effects of exercise in mesothelioma.
  • At Federation University the Berzins group has identified a significant defect in the frequency of mucosal associated invariant T cells in the blood and tumour tissue of patients with lung cancer compared to blood from healthy donors. The project will characterise these cells in patients with lung cancer using different functional assays and investigate the significance of the defect by studying the interactions between MAIT cells and the tumor cells.

Continuing its support of lung cancer research, LFA is establishing three new co-funded PhD scholarships and a call for expressions of interest will be made in the coming weeks. The LFA annual $10,000 grant-in-aid will open for applications at the same time. If your institution is interested to partner, co-fund and administer these scholarships, and for more information about the application process, contact Glenda Colburn, Director – Lung Cancer National Program.